Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study

Current Medical Research and Opinion

Volumn 30, Issue 3, 2014, Pages 447-461

  Carrato, A ^a   Vergnenegre A ^b   Thomas, M ^c   McBride, K ^d   Medina, J ^e   Cruciani, G ^f  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b Hopital du Cluzeau   (France)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d Instat Consulting Inc   (United States)

^e ASTRAZENECA   (United Kingdom)

^f SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

Author keywords

Carcinoma; Disease management; Epidemiology; Europe; Non small cell lung; Treatment outcomes

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BLOOD; BONE MARROW; CLINICAL PRACTICE; DISEASE MARKER; EUROPE; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; EUROPE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84896705821     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.860372     Document Type: Article

References (18)

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005;16:481-8
2. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-80
3. Crino L, Weder W, van Meerbeeck J, et al. Early stage and locally advanced (non-metastatic) non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v103-15
4. D'Addario G, Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20(Suppl 4):68-70
5. Peters S, Adjei AA, Gridelli C, et al. Metastatic non-small cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii56-64
6. Freeman DH. Applied Categorical Data Analysis. New York: Marcel Dekker Inc., 1987
7. Sobin LH, Wittekind C. TNM Classification of Malignant Tumours, 6th edn. Hoboken, NJ: John Wiley & Sons, 2002
8. Devesa SS, Bray F, Vizcaino AP, et al. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005;117:294-9
9. Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584-94
10. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409
11. Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 2012;307:2418-29
12. Parsons A, Daley A, Begh R, et al. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ 2010;340:b5569
13. Reck M, Gatzemeier U. Advanced non-small cell lung cancer therapy: historical and future perspectives. Targ Oncol 2008;3:135-47
14. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362: 2380-8
15. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57
16. Rosell R, Gervais R, Vergnenegre A, et al. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. J Clin Oncol 2011;29(Suppl 15):Abstract 7503
17. Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011;29:2121-7
18. Kelly K, Crowley J, Bunn Jr PA, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-18